Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

SELL
$8.96 - $11.69 $12.5 Million - $16.3 Million
-1,395,253 Reduced 71.92%
544,720 $5.27 Million
Q1 2023

May 15, 2023

SELL
$5.94 - $11.27 $1.44 Million - $2.74 Million
-243,173 Reduced 11.14%
1,939,973 $21.3 Million
Q4 2022

Feb 14, 2023

BUY
$4.11 - $8.14 $8.97 Million - $17.8 Million
2,183,146 New
2,183,146 $9.43 Million
Q2 2021

Aug 16, 2021

SELL
$10.0 - $14.52 $3.15 Million - $4.57 Million
-314,565 Closed
0 $0
Q1 2021

May 17, 2021

SELL
$12.3 - $18.73 $22.4 Million - $34.2 Million
-1,824,896 Reduced 85.3%
314,565 $4.09 Million
Q4 2020

Feb 16, 2021

SELL
$12.94 - $16.05 $2.64 Million - $3.28 Million
-204,290 Reduced 8.72%
2,139,461 $29.6 Million
Q3 2020

Nov 16, 2020

SELL
$13.19 - $16.66 $19.8 Million - $25 Million
-1,499,990 Reduced 39.02%
2,343,751 $34.5 Million
Q2 2020

Aug 14, 2020

SELL
$14.12 - $18.33 $11.7 Million - $15.1 Million
-825,602 Reduced 17.68%
3,843,741 $62.5 Million
Q1 2020

May 15, 2020

BUY
$11.34 - $21.46 $12.2 Million - $23 Million
1,073,710 Added 29.86%
4,669,343 $67.8 Million
Q4 2019

Feb 14, 2020

BUY
$3.88 - $21.42 $13.9 Million - $76.6 Million
3,573,880 Added 16429.37%
3,595,633 $72.8 Million
Q3 2019

Nov 15, 2019

SELL
$5.34 - $6.59 $1,762 - $2,174
-330 Reduced 1.49%
21,753 $116,000
Q2 2019

Aug 14, 2019

BUY
$6.05 - $6.75 $116,256 - $129,708
19,216 Added 670.25%
22,083 $145,000
Q1 2019

May 15, 2019

BUY
$6.06 - $7.64 $17,374 - $21,903
2,867 New
2,867 $19,000
Q1 2018

May 15, 2018

SELL
$4.85 - $5.99 $2.6 Million - $3.22 Million
-537,000 Closed
0 $0
Q4 2017

Feb 14, 2018

BUY
$4.53 - $7.09 $2.43 Million - $3.81 Million
537,000
537,000 $2.43 Million

Others Institutions Holding AUPH

About Aurinia Pharmaceuticals Inc.


  • Ticker AUPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,892,000
  • Market Cap $1.16B
  • Description
  • Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...
More about AUPH
Track Steven Cohen's Portfolio

Track Steven Cohen Portfolio

Follow Steven Cohen (Point72 Asset Management, L.P.) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.